Anxiety and depression are debilitating, costly psychological disorders that account for more than $133 billion annually in direct medical expenses in the United States. Finding alternative treatments to reduce the personal and financial burden for patients with these disorders, while maintaining patient safety, is vital. The purposes of this study were to determine if crocin, a compound from saffron (Crocus sativus L), produces anxiolytic and/or antidepressant effects using rat models for anxiety and behavioral despair and to determine the effects of crocin at the benzodiazepine site on the γ-aminobutyric acid type A receptor. Fifty-five male Sprague Dawley rats were randomly assigned to 1 of 5 groups: vehicle (dimethyl sulfoxide), crocin, midazolam, flumazenil plus crocin, and midazolam plus crocin. Behavioral analyses were conducted in the elevated plus-maze and the forced swim test. Data were analyzed using multivariate analysis of variance and a least significant difference post hoc test. Data from the elevated plus-maze suggested crocin may attenuate the anxiolytic effects of midazolam, while not affecting psychomotor activity. Data from the forced swim test showed a significant increase in mean time mobile in the midazolam plus crocin group, suggesting a decrease in behavioral despair because of the interaction between crocin and midazolam.
Keywords: Adverse patient outcomes; closed claims research; hypoventilation; respiratory complications; standard of care.
Copyright© by the American Association of Nurse Anesthetists.